Subretinal delivery of RGX-314 AAV8-anti-VEGF Fab gene therapy in NHP
Anna Tretiakova(Pfizer (United States)), James M. Wilson(St Bartholomew's Hospital), Leah Makaron(University of Pennsylvania), Jean Bennett(Penn Presbyterian Medical Center), Erin Bote(University of Pennsylvania), Tomás S. Alemán(Children's Hospital of Philadelphia), Elaine Zhou(University of Pennsylvania), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Albert M. Maguire(Children's Hospital of Philadelphia), Stephen Yoo(Cedars-Sinai Medical Center), Erik Wielechowski(University of Pennsylvania), Arkady Lyubarsky(Penn Presbyterian Medical Center)
Investigative Ophthalmology & Visual Science
June 23, 2017
Cited by 2
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703